IRadimed 3Q 2026: Revenue $24.2M, EPS $0.51— 10-Q Summary

What happened

IRadimed reported third-quarter 2026 revenue of $24.2 million, up 14% from a year earlier. Net income rose 16.7% to $6.5 million, and diluted earnings per share rose to $0.51 from $0.43.

Confirmed

Global impact / market context

Faster profit growth than sales growth suggests the company kept more of each sales dollar, which means costs grew slower than revenue. That matters for investors because improving profit per sale can support future cash available for manufacturing capacity and product development.

Analyst inference

Medical device makers rely on recurring sales of accessories and disposables, which can steady revenue between equipment orders. International revenue grew 45% in the quarter while U.S. sales rose 9%, so overseas demand drove much of the growth. Completed facility expansion adds capacity.

Analyst inference

What to watch

1. Nine-month revenue rose 9% to $66.6 million. International revenue grew 45% in the quarter and 37% year to date, while U.S. sales rose 9% and 4%. Watch whether that gap narrows or widens. Confirmed
2. The expanded manufacturing facility and new executive offices were completed, adding capacity to support growth. Watch whether that added capacity is used, because unused capacity raises costs per unit and can pressure profit per sale. Confirmed
3. Management expects fiscal 2026 revenue to exceed 2025 levels, supported by medical devices, accessories, disposables and services. Watch whether quarterly sales and profit per sale support that expectation, since it is a forecast, not a confirmed result. Proposed

Evidence

• Original source link unavailable